135 related articles for article (PubMed ID: 37949486)
21. Evaluation of follow-up strategies for women with epithelial ovarian cancer following completion of primary treatment.
Zachou G; El-Khouly F; Dilley J
Cochrane Database Syst Rev; 2023 Aug; 8(8):CD006119. PubMed ID: 37650760
[TBL] [Abstract][Full Text] [Related]
22. Prognostic role of Ca125 response criteria and RECIST criteria: analysis of results from the MITO-3 phase III trial of gemcitabine versus pegylated liposomal doxorubicin in recurrent ovarian cancer.
Ferrandina G; Ludovisi M; Corrado G; Carone V; Petrillo M; Scambia G
Gynecol Oncol; 2008 May; 109(2):187-93. PubMed ID: 18343487
[TBL] [Abstract][Full Text] [Related]
23. CA125-related measures of tumor kinetics and outcome of patients with recurrent ovarian cancer receiving chemotherapy: a retrospective evaluation.
Colloca G; Venturino A; Addamo G; Coccorullo Z; Ratti R; Caltabiano G; Guarneri D
Jpn J Clin Oncol; 2013 Dec; 43(12):1203-9. PubMed ID: 24038194
[TBL] [Abstract][Full Text] [Related]
24. [Clinical value of the estimation of growth kinetics of primary ovarian cancer recurrences by CA125 doubling time].
Riedinger JM; Coudert B; Barillot I; Buffenoir G; Mayer F; Fargeot P; Cuisenier J; Guerrin J
Bull Cancer; 1997 Sep; 84(9):855-60. PubMed ID: 9435806
[TBL] [Abstract][Full Text] [Related]
25. Prediction effects of serum CA125 decrease ratio during different cycles in relapsed ovarian cancer.
Wang J; Liu Y; Li J; Lu X
J Obstet Gynaecol Res; 2019 May; 45(5):1006-1011. PubMed ID: 30687999
[TBL] [Abstract][Full Text] [Related]
26. Normal serum CA125 half-life and normal serum nadir CA125 level in patients with ovarian cancers.
Yoshikawa T; Takano M; Kita T; Kudoh K; Sasaki N; Kato M; Watanabe A; Miyamoto M; Goto T; Furuya K
Eur J Gynaecol Oncol; 2012; 33(3):269-73. PubMed ID: 22873097
[TBL] [Abstract][Full Text] [Related]
27. Taxane monotherapy regimens for the treatment of recurrent epithelial ovarian cancer.
Patel A; Kalachand R; Busschots S; Doherty B; Kapros E; Lawlor D; Hall N; Stordal BK
Cochrane Database Syst Rev; 2022 Jul; 7(7):CD008766. PubMed ID: 35866378
[TBL] [Abstract][Full Text] [Related]
28. Prognostic Significance of CA125 Dynamic Change for Progression Free Survival in Patients with Epithelial Ovarian Carcinoma.
Li Z; Yin H; Ren M; Shen Y
Med Sci Monit; 2020 Sep; 26():e925051. PubMed ID: 32908118
[TBL] [Abstract][Full Text] [Related]
29. CA-125 KELIM as a Potential Complementary Tool for Predicting Veliparib Benefit: An Exploratory Analysis From the VELIA/GOG-3005 Study.
You B; Sehgal V; Hosmane B; Huang X; Ansell PJ; Dinh MH; Bell-McGuinn K; Luo X; Fleming GF; Friedlander M; Bookman MA; Moore KN; Steffensen KD; Coleman RL; Swisher EM
J Clin Oncol; 2023 Jan; 41(1):107-116. PubMed ID: 35867965
[TBL] [Abstract][Full Text] [Related]
30. [Diagnostic and prognostic value of tumor markers, scores (clinical and biological) algorithms, in front of an ovarian mass suspected of an epithelial ovarian cancer: Article drafted from the French Guidelines in oncology entitled "Initial management of patients with epithelial ovarian cancer" developed by FRANCOGYN, CNGOF, SFOG, GINECO-ARCAGY under the aegis of CNGOF and endorsed by INCa].
Bendifallah S; Body G; Daraï E; Ouldamer L
Gynecol Obstet Fertil Senol; 2019 Feb; 47(2):134-154. PubMed ID: 30733191
[TBL] [Abstract][Full Text] [Related]
31. Perioperative changes in serum CA125 levels: a prognostic factor for disease-specific survival in patients with ovarian cancer.
Zwakman N; van de Laar R; Van Gorp T; Zusterzeel PL; Snijders MP; Ferreira I; Massuger LF; Kruitwagen RF
J Gynecol Oncol; 2017 Jan; 28(1):e7. PubMed ID: 27670261
[TBL] [Abstract][Full Text] [Related]
32. [Prognostic value of CA125 half-life and early normalization during chemotherapy in advanced ovarian tumors: results of a multicentric French study].
Riedinger JM
Bull Cancer; 2007 Mar; 94(3):287-95. PubMed ID: 17371771
[TBL] [Abstract][Full Text] [Related]
33. Postoperative human epididymis protein 4 predicts primary therapy outcome in advanced epithelial ovarian cancer.
Vallius T; Hynninen J; Auranen A; Matomäki J; Oksa S; Roering P; Grènman S
Tumour Biol; 2017 Feb; 39(2):1010428317691189. PubMed ID: 28218038
[TBL] [Abstract][Full Text] [Related]
34. Luteinising hormone releasing hormone (LHRH) agonists for the treatment of relapsed epithelial ovarian cancer.
Wuntakal R; Seshadri S; Montes A; Lane G
Cochrane Database Syst Rev; 2016 Jun; 2016(6):CD011322. PubMed ID: 27356090
[TBL] [Abstract][Full Text] [Related]
35. CA125 surveillance increases optimal resectability at secondary cytoreductive surgery for recurrent epithelial ovarian cancer.
Fleming ND; Cass I; Walsh CS; Karlan BY; Li AJ
Gynecol Oncol; 2011 May; 121(2):249-52. PubMed ID: 21300398
[TBL] [Abstract][Full Text] [Related]
36. CA125 level as a predictor of progression-free survival and overall survival in ovarian cancer patients with surgically defined disease status prior to the initiation of intraperitoneal consolidation therapy.
Juretzka MM; Barakat RR; Chi DS; Iasonos A; Dupont J; Abu-Rustum NR; Poynor EA; Aghajanian C; Spriggs D; Hensley ML; Sabbatini P
Gynecol Oncol; 2007 Jan; 104(1):176-80. PubMed ID: 16996584
[TBL] [Abstract][Full Text] [Related]
37. PARAGON (ANZGOG-0903): a phase 2 study of anastrozole in asymptomatic patients with estrogen and progesterone receptor-positive recurrent ovarian cancer and CA125 progression.
Kok PS; Beale P; O'Connell RL; Grant P; Bonaventura T; Scurry J; Antill Y; Goh J; Sjoquist K; DeFazio A; Mapagu C; Amant F; Friedlander M;
J Gynecol Oncol; 2019 Sep; 30(5):e86. PubMed ID: 31328463
[TBL] [Abstract][Full Text] [Related]
38. High grade, advanced, serous ovarian cancer with low serum CA125 levels.
Asali A; Haj-Yehia N; Zehavi T; Perry T; Beiner M; Fishman A; Kadan Y
J Obstet Gynaecol; 2021 Oct; 41(7):1107-1111. PubMed ID: 33427544
[TBL] [Abstract][Full Text] [Related]
39. The significance of the pattern of serum CA125 level ascent to above the normal range in epithelial ovarian, primary peritoneal and tubal carcinoma patients.
Levy T; Weiser R; Boaz M; Ben Shem E; Golan A; Menczer J
Gynecol Oncol; 2013 Apr; 129(1):165-8. PubMed ID: 23274778
[TBL] [Abstract][Full Text] [Related]
40. Evaluation of follow-up strategies for patients with epithelial ovarian cancer following completion of primary treatment.
Clarke T; Galaal K; Bryant A; Naik R
Cochrane Database Syst Rev; 2014 Sep; 2014(9):CD006119. PubMed ID: 25198378
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
